Conclusion: Adminstration of normal dose of anastrazole
decreases serum estrogen levels.
These trials indicate that tamoxifen (a selective estrogen receptor modulator-SERM), raloxifene (also a SERM), exemestane (an aromatase inhibitor) and anastrazole
(an aromatase inhibitor), can all effectively reduce the risk of breast cancer if administered daily for five years (35).
Aromatase inhibitors, such as exemestane, anastrazole
, and letrazole, are drugs which block this conversion in peripheral tissues.
The independent prognostic and predictive role of PR expression irrespective of ER has been a subject of great controversy as demonstrated by the report from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant trial, a large worldwide trial comparing the efficacy of tamoxifen with that of the aromatase inhibitor anastrazole
, showing overall that patients with ER+/PR+ tumours had a lower recurrence rate than those with ER+/PR-tumours.3 In the present study the percentage of ER/PR+ patients was 76/120 (63.33%) however the percentage of ER/PR-patients was 20/120 (16.83%) and after that the percentage of ER+ and PR-patients was 16/120 (13.33%).
The protection observed with the anastrazole
treatment of the previous study was corroborated by a study with metformin treatment which reversed PAH and decreased pulmonary vascular remodeling via aromatase inhibition .
Medications, including tamoxifen and anastrazole
, have been recommended.
, which is a an aromatase inhibiting drug which effectively treats advanced breast cancer, is strongly linked to osteoporosis and causing especially low bone density of the femur (Mutlu et.
SABRE trial included in this study investigated the effects of adjuvant anastrazole
with or without risedronate on BMD in postmenopausal women with hormone responsive early breast cancer and preexisting lower, moderate, and higher risk of fragility fracture.
Presumably most of the ER+ patients were taking tamoxifen or anastrazole
for years after their diagnosis.
A recent study published in the New England Journal of Medicine showed that a combination of anastrazole
(Arimidex[R]) and fulvestrant (Faslodex[R]) improved the overall survival and progression-free survival in women with certain hormone-receptor positive metastatic breast cancers.*
This was managed using palliative radiotherapy to control the symptoms and her adjuvant hormonal therapy was switched to Anastrazole
(AstraZeneca plc, London, United Kingdom).
Los inhibidores de aromatasa anastrazole
y letrozole son utilizados con exito en la terapeutica del cancer de mama (64).